Clinical Relevance of the Standardized Uptake Value (Suv) in Staging Breast Cancer with FDG-PET/CT

Dokkyo Journal of Medical Sciences

Volumn 34, Issue 3, 2007, Pages 193-204

  Zytoon, Ashraf Anas ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Breast cancer; Fdg pet ct suvmax; Lymph node spread; Metastasis

Indexed keywords

CA 15-3 ANTIGEN; FLUORODEOXYGLUCOSE F 18; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CALCULATION; CANCER DIAGNOSIS; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DIAGNOSTIC PROCEDURE; EARLY DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; LINEAR REGRESSION ANALYSIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; OUTCOME ASSESSMENT; PREDICTION; PREOPERATIVE EVALUATION; SENSITIVITY AND SPECIFICITY;

EID: 38749107589     PISSN: 03855023     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. : Cancer statistics, 2003. CA Cancer J Clin., 53 : 5-26, 2003.
2. Scheidhauer K, Walter C, Seemann MD. : FDG PET and other imaging modalities in the primary diagnosis of suspicious breast lesions. Eur J Nucl Med Mol Imaging, 31(suppl 1) : S70-S79, 2004.
3. Delbeke D. : Oncological applications of FDG PET imaging : brain tumors, colorectal cancer, lymphoma and melanoma. J Nucl Med. 40 : 591-603, 1999.
4. Coleman RE. : PET in lung cancer. J Nucl Med. 40 : 814-820, 1999.
5. Delbeke D. : Oncological applications of FDG PET imaging. J Nucl Med. 40 : 1706-1715, 1999.
6. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. : A tabulated summary of the FDG PET literature. J Nucl Med, 42 Suppl 1 : 1S-93S, 2001.
7. Wahl RL. : Current status of PET in breast cancer imaging, staging, and therapy. Semin Roentgenol, 36 : 250-260, 2001.
8. Rose C, Dose J, Avril N. : Positron emission tomography for the diagnosis of breast cancer. Nucl Med Commun, 23 : 613-618, 2002.
9. Dehdashti F, Siegel BA. : Evaluation of breast and gynecologic cancers by positron emission tomography. Semin Roentgenol, 37 : 151-168, 2002.
10. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med, 44 : 224-239, 2003.
11. Lorna Weir, Daniel Worsley, Vanessa Bernstein. : The value of FDG positron emission tomography in the management of patients with breast cancer. The Breast Journal, 11 : 204-209, 2005.
12. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, et al. : A combined PET/CT scanner for clinical oncology. J Nucl Med, 41 : 1369-1379, 2000.
13. Ell PJ, Von Schulthess GK. : PET/CT : a new road map [editorial]. Eur J Nucl Med Mol Imaging, 29 : 719-720, 2002.
14. Cohade C, Wahl RL. : Applications of positron emission tomography/computed tomography image fusion in clinical positron emission tomography - clinical use, interpretation methods, diagnostic improvements. Semin Nucl Med, 33 : 228-237, 2003.
15. Mitsuaki Tatsumi, Christian Cohade, Karen A, Mourtzikos, et al. : Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging, 33 : 254-262, 2006.
16. Schirrmeister H, Kuhn T, Guhlmann A, et al. : Fluorine-18 2-deoxy-2-fluoro-Dglucose PET in the preoperative staging of breast cancer : Comparison with the standard staging procedures. Eur J Nucl Med. 28 : 351-358, 2001.
17. Dose J, Bleckmann C, Bachmann S, et al. : Comparison of fluorodeoxyglucose positron emission tomography and conventional diagnostic procedures for the detection of distant metastases in breast cancer patients. Nucl Med Commun, 23 : 857-864, 2002.
18. Nancy A. : Obuchowski. Receiver Operating Characteristic Curves and Their Use in Radiology. Radiology, 229 : 3-8, 2003.
19. 18F]-D-glucose. Cancer. 82 : 2227-2234, 1998.
20. 18F] 2-Deoxy-2-fluoro-D-glucose-positron emission tomography. J Cancer Res Clin Oncol, 130 : 273-278, 2004.
21. Henderik L. van Westreenen, John T. M. Plukker, David C. P. Cobben et al. : Prognostic Value of the Standardized Uptake Value in Esophageal Cancer. AJR, 185 : 436-440, 2005.
22. Robert J. Cerfolio, and Ayesha S. Bryant. : Maximum Standardized Uptake Values on Positron Emission Tomography of Esophageal Cancer Predicts Stage, Tumor Biology, and Survival. Ann Thorac Surg, 82 : 391-395, 2006.
23. 18F-Fluoro-2-Deoxy-Glucose-Positron Emission Tomography Scan in Non-Small-Cell Lung Cancer : An Analysis of 125 Cases. J Clin Oncol. 17 : 3201-3206, 1999.
24. Robert J. Cerfolio, Ayesha S. Bryant, Buddhiwardhan Ohja, Alfred A. Bartolucci. : The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg, 130 : 151-159, 2005.
25. Dirk Hellwig, Andreas Gröschel, Thomas P. Graeter, et al. : Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging, 33 : 13-21, 2006.
26. Allal AS, Dulguerov P, Allaoua M, Haenggeli CA. Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol, 20 : 1398-1404, 2002.
27. Greco M, Crippa F, Agresti R. : Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography : clinical evaluation and alternative management. J Natl Cancer Inst, 93 : 630-635, 2001.
28. Pecking AP, Mechelany-Corone C, Bertrand-Kermorgant F. : Detection of occult disease in breast cancer using fluorodeoxyglucose camera-based positron emission tomography. Clin Breast Cancer, 2 : 229-234, 2001.
29. Gion M, Boracchi P, Dittadi R, et al. : Prognostic role of serum CA 15.3 in 362 node-negative breast cancers. An old player for a new game. Eur J Cancer, 38 : 1181-1188, 2002.
30. Gion M, Barioli P, Mione R, et al. : Tumor markers in breast cancer follow-up : a potentially useful parameter still awaiting definitive assessment. Ann Oncol, 6 Suppl 2 : 31-35, 1995.
31. Ravaioli A, Pasini G, Polselli A, Papi M, Tassinari D, Arcangeli V, Milandri C, Amadori D, Bravi M, Rossi D, Fattori PP, Pasquini E, Panzini I. : Staging of breast cancer : new recommended standard procedure. Breast Cancer Res Treat, 72 : 53-60, 2002.
32. De La Lande B, Hacene K, Floiras JL, Alatrakchi N, Pichon MF. Prognostic value of CA 15.3 kinetics for metastatic breast cancer. Int J Biol Markers, 17 : 231-238, 2002.
33. 18F-FDG PET : histologic and immunohistochemical tissue analysis. J Nucl Med, 42 : 9-16, 2001.
34. Bombardieri E, Crippa F. : PET imaging in breast cancer. J Nucl Med, 45 : 245-256, 2001.
35. Bombardieri E, Crippa F, Baio SM, Peeters BA, Greco M, Pauwels EK : Nuclear medicine advances in breast cancer imaging. Tumori, 87 : 277-287, 2001.
36. William B, Eubank David Mankoff Mallar Bhattacharya, et al. : Impact of FDG PET on Defining the Extent of Disease and on the Treatment of Patients with Recurrent or Metastatic Breast Cancer. AJR, 183 : 479-486, 2004.
37. Moon DH, Maddahi J, Silverman DHS, et al. : Accuracy of whole-body [fluorine-18]-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med. 39 : 431-435, 1998.
38. 18Fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol. 19 : 3516-3523, 2001.
39. 18fluorodeoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res. 17 : 1687-1692, 1997.
40. Dose J, Bleckmann C, Bachmann S, et al. : Comparison of fluorodeoxyglucose positron emission tomography and "conventional diagnostic procedures" for the detection of distant metastases in breast cancer patients. Nucl Med Commun, 23 : 857-864, 2002.
41. Siggelkow W, Zimny M, Faridi A, Petzold K, Buell U, Rath W. : The value of positron emission tomography in the follow-up for breast cancer. Anticancer Res. 23 : 1859-1868, 2003.
42. Takayoshi Uematsu, Sachiko Yuen, Seigo Yukisawa, et al. : Comparison of FDG PET and SPECT for Detection of Bone Metastases in Breast Cancer. AJR, 184 : 1266-1273, 2005.